comprehensive -WSS

comprehensive

author：Wikipedia 2025-08-23 18:37:25 - browse：2337

Adam's take main illustration — Molly Ferguson/STAT

This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes to the HELIOS-B study and talking up its hypertension treatment, and quick takes on Amylyx and obesity stocks.

A Worst CEO gets some much-needed help

For most of last year, Ocular Therapeutix CEO Antony Mattessich promised shareholders that he was close to nailing down a lucrative pharma partnership that would pay for late-stage clinical trials of the company’s treatments for degenerative eye diseases. The deal never happened. I heard from many Ocular investors who were frustrated and angry about Mattesich’s poor job performance. He ended up earning a spot last year on my worst biopharma CEO list. It was an easy pick.

On Thursday, Ocular announced a meaningful “leadership update.” Mattessich is still the CEO, but let’s just say the company’s board decided to surround him with new executives and retinal experts with proven track records of getting stuff done.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Harvard's David Sinclair gets blowback over aging

knowledge

WSS

General Catalyst, Summa Health deal will turn on physician buy

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Novo Nordisk to expand supply of Wegovy for U.S. patients

He's 19 months old and has one of the world’s rarest diseases

Readout Newsletter: BridgeBio, Akero, and human embryo models

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

knowledge

comprehensive

A Worst CEO gets some much-needed help

focus

Duchenne breakthrough therapy leaves behind pioneering families

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Malaria cases in Florida and Texas: Here’s what you need to know

Novo Nordisk to expand supply of Wegovy for U.S. patients

Medicare proposal to cover medical devices draws a mixed reaction

Ancient Greek ideas underpin modern concepts of pregnancy

Dobbs anniversary: the lost opportunity of abortion as health care

Cognito secures funding to test medical device for Alzheimer's

BioMarin wins approval for gene therapy to treat hemophilia A

What we need to know about Arena Bioworks

hotspot

Even great ERs can’t make up for American health disparities

Stem cell biologist probes earliest stages of human development

What we need to know about Arena Bioworks

Families look for replacement for GSK asthma drug Flovent

Novo Nordisk to expand supply of Wegovy for U.S. patients

FDA drug safety: Singulair case shows systemic surveillance flaws

Wikipedia

knowledge

focus

focus